Work

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

Year: 2024

Type: article

Source: The Lancet Infectious Diseases

DOI: 10.1016/s1473-3099(24)00357-8

Authors: Robert McMahon, Sebastian Toepfer, Natascha Sattler, Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Romana Hochreiter, Karin Kosulin, Robert Mader, Oliver Zoihsl, Nina Wressnigg, Katrin Dubischar, Vera Buerger, Susanne Eder-Lingelbach, Juan-Carlos Jaramillo

Institution: Valneva (Austria)

Language: English

Topic: Mosquito-borne diseases and control

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Coalition for Epidemic Preparedness Innovations, H2020 Fast Track to Innovation

OpenAlex ID: W4401503247

FWCI: 17.25

Cites: 28

Cited by: 52

Related to: 10